IJCM  Vol.8 No.3 , March 2017
Hyperuricemia as a Predictor of Progression of Chronic Kidney Disease: A Matched Cohort Analysis
Abstract: Background: The clinical significance of uric acid (UA) in patients with chronic kidney disease (CKD) has never been elucidated in detail. Objectives: The aim of this study was to elucidate the predictive value of hyperuricemia (HU) in relation to kidney disease progression in CKD patients. Methods: We reviewed data obtained from 201 CKD patients. Renal outcome was assessed by performing the Kaplan-Meier and Cox proportional hazard regression models. The renal outcomes of CKD patients with and without HU were compared by using a propensity score-matched cohort. Results: The results of a multivariate Cox regression analysis showed that HU (UA ≥ 7.1 mg/dL) (P = 0.001), diabetes mellitus (P = 0.003), and a high urine albumin-to-creatinine ratio (P = 0.0005) were significantly associated with a ≥50% eGFR decline or ESRD. The serum UA values were positively correlated with mean blood pressure (P = 0.007), visceral fat area (P = 0.0003), and maximum carotid intima-media thickness (P = 0.0003). The Kaplan-Meier analysis in the propensity score-matched cohort indicated that the renal survival rate of the group of CKD patients with HU was significantly lower than that of the group without HU (log rank, P < 0.0001), even after complete adjustment for the eGFR. Conclusion: The results of this study suggest that the serum UA value is a predictor of CKD progression.
Cite this paper: Kamiyama, M. , Kataoka, H. , Moriyama, T. , Mochizuki, T. and Nitta, K. (2017) Hyperuricemia as a Predictor of Progression of Chronic Kidney Disease: A Matched Cohort Analysis. International Journal of Clinical Medicine, 8, 178-197. doi: 10.4236/ijcm.2017.83018.

[1]   Nenov, V.D., Taal, M.W., Sakharova, O.V. and Brenner, B.M. (2000) Multi-Hit Nature of Chronic Renal Disease. Current Opinion in Nephrology and Hypertension, 29, 85-97.

[2]   Taal, M.W. and Brenner, B.M. (2006) Predicting Initiation and Progression of Chronic Kidney Disease: Developing Renal Risk Scores. Kidney International, 70, 1694-1705.

[3]   Goicoechea, M., Garcia de Vinuesa, S., Verdalles, U., Verde, E., Macias, N., et al. (2015) Allopurinol and Progression of CKD and Cardiovascular Events: Long-Term Follow-Up of a Randomized Clinical Trial. American Journal of Kidney Diseases, 65, 543-549.

[4]   Momoki, K., Kataoka, H., Moriyama, T., Mochizuki, T. and Nitta, K. (2016) Hyperuricemia as a Predictive Marker for Progression of Nephrosclerosis: Clinical Assessment of Prognostic Factors in Biopsy-Proven Arterial/Arteriolar Nephrosclerosis. Journal of Atherosclerosis and Thrombosis.

[5]   Dousdampanis, P., Trigka, K., Musso, C.G. and Fourtounas, C. (2014) Hyperuricemia and Chronic Kidney Disease: An Enigma Yet to Be Solved. Renal Failure, 36, 1351-1359.

[6]   Giordano, C., Karasik, O., King-Morris, K. and Asmar, A. (2015) Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. Disease Markers, 2015, 382918.

[7]   Borghi, C., Rosei, E.A., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J.T., et al. (2015) Serum Uric Acid and the Risk of Cardiovascular and Renal Disease. Journal of Hypertension, 33, 1729-1741.

[8]   Nacak, H., van Diepen, M., Qureshi, A.R., Carrero, J.J., Stijnen, T., et al. (2015) Uric Acid is Not Associated with Decline in Renal Function or Time to Renal Replacement Therapy Initiation in a Referred Cohort of Patients with Stage III, IV and V Chronic Kidney Disease. Nephrology Dialysis Transplantation, 30, 2039-2045.

[9]   Uchida, S., Chang, W.X., Ota, T., Tamura, Y., Shiraishi, T., Kumagai, T., et al. (2015) Targeting Uric Acid and the Inhibition of Progression to End-Stage Renal Disease—A Propensity Score Analysis. PLoS One, 10, e0145506.

[10]   Iseki, K., Ikemiya, Y., Inoue, T., Iseki, C., Kinjo, K. and Takishita, S. (2004) Significance of Hyperuricemia as a Risk Factor for Developing ESRD in a Screened Cohort. American Journal of Kidney Diseases, 44, 642-650.

[11]   Madero, M., Sarnak, M.J., Wang, X., Greene, T., Beck, G.J., Kusek, J.W., et al. (2009) Uric Acid and Long-Term Outcomes in CKD. American Journal of Kidney Diseases, 53, 796-803.

[12]   Takahashi, S., Yamamoto, T., Tsutsumi, Z., Moriwaki, Y., Yamakita, J. and Higashino, K. (1997) Close Correlation between Visceral fat Accumulation and Uric Acid Metabolism in Healthy Men. Metabolism, 6, 1162-1165.

[13]   Kanbay, M., Jensen, T., Solak, Y., Le, M., Roncal-Jimenez, C., Rivard, C., et al. (2016) Uric Acid in Metabolic Syndrome: From an Innocent Bystander to a Central Player. European Journal of Internal Medicine, 29, 3-8.

[14]   Ishizaka, N., Ishizaka, Y., Toda, E., Nagai, R. and Yamakado, M. (2005) Association between Serum Uric Acid, Metabolic Syndrome, and Carotid Atherosclerosis in Japanese Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1038-1044.

[15]   Levey, A.S., Eckardt, K.U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., et al. (2005) Definition and Classification of Chronic Kidney Disease: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 67, 2089-2100.

[16]   Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., et al. (2009) Revised Equations for Estimated GFR from Serum Creatinine in Japan. American Journal of Kidney Diseases, 53, 982-992.

[17]   Spooner, R.J., Weir, R.J. and Frier, B.M. (1987) Detection of Microalbuminuria in Diabetic Patients Using a Simple Latex Agglutination Test. Clinica Chimica Acta, 166, 247-253.

[18]   Lash, T.L., Mor, V., Wieland, D., Ferrucci, L., Satariano, W. and Silliman, R.A. (2007) Methodology, Design, and Analytic Techniques to Address Measurement of Comorbid Disease. Journal of Gerontology Series A: Biological Sciences and Medical Sciences, 62, 281-285.

[19]   Ording, A.G. and Sorensen, H.T. (2013) Concepts of Comorbidities, Multiple Morbidities, Complications, and Their Clinical Epidemiologic Analogs. Clinical Epidemiology, 5, 199-203.

[20]   Borkan, G.A., Gerzof, S.G., Robbins, A.H., Hults, D.E., Silbert, C.K. and Silbert, J.E. (1982) Assessment of Abdominal Fat Content by Computed Tomography. American Journal of Clinical Nutrition, 36, 172-177.

[21]   Grauer, W.O., Moss, A.A., Cann, C.E. and Goldberg, H.I. (1984) Quantification of Body Fat Distribution in the Abdomen Using Computed Tomography. American Journal of Clinical Nutrition, 39, 631-637.

[22]   De Bray, J.M., Baud, J.M., Delanoy, P., Camuzat, J.P., Dehans, V., Descamp-Le Chevoir, J., et al. (1998) Reproducibility in Ultrasonic Characterization of Carotid Plaques. Cerebrovascular Diseases, 8, 273-277.

[23]   Liang, M.H. and Fries, J.F. (1978) Asymptomatic Hyperuricemia: The Case for Conservative Management. Annals of Internal Medicine, 88, 666-670.

[24]   Bose, B., Badve, S.V., Hiremath, S.S., Boudville, N., Brown, F.G., Cass, A., et al. (2014) Effects of Uric Acid-Lowering Therapy on Renal Outcomes: A Systematic Review and Meta-Analysis. Nephrology Dialysis Transplantation, 29, 406-413.

[25]   Weiner, D.E., Tighiouart, H., Elsayed, E.F., Griffith, J.L., Salem, D.N. and Levey, A.S. (2008) Uric Acid and Incident Kidney Disease in the Community. Journal of American Society of Nephrology, 19, 1204-1211.

[26]   Bellomo, G., Venanzi, S., Verdura, C., Saronio, P., Esposito, A. and Timio, M. (2010) Association of Uric Acid with Change in Kidney Function in Healthy Normotensive Individuals. American Journal of Kidney Diseases, 56, 264-272.

[27]   Zoppini, G., Targher, G., Chonchol, M., Ortalda, V., Abaterusso, C., Pichiri, I., et al. (2012) Serum Uric Acid Levels and Incident Chronic Kidney Disease in Patients with Type 2 Diabetes and Preserved Kidney Function. Diabetes Care, 35, 99-104.

[28]   Ficociello, L.H., Rosolowsky, E.T., Niewczas, M.A., Maselli, N.J., Weinberg, J.M, Aschengrau, A., et al. (2010) High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes: Results of a 6-Year Follow-Up. Diabetes Care, 33, 1337-1343.

[29]   Ohno, I., Hosoya, T., Gomi, H., Ichida, K., Okabe, H. and Hikita, M. (2001) Serum Uric Acid and Renal Prognosis in Patients with IgA Nephropathy. Nephron, 87, 333-339.

[30]   Syrjanen, J., Mustonen, J. and Pasternack, A. (2000) Hypertriglyceridaemia and Hyperuricaemia Are Risk Factors for Progression of IgA Nephropathy. Nephrology Dialysis Transplantation, 5, 34-42.

[31]   Wu, J., Chen, X., Xie, Y., Yamanaka, N., Shi, S., Wu, D., et al. (2005) Characteristics and Risk Factors of Intrarenal Arterial Lesions in Patients with IgA Nephropathy. Nephrology Dialysis Transplantation, 20, 719-727.

[32]   Moriyama, T., Itabashi, M., Takei, T., Kataoka, H., Sato, M., Shimizu, A., et al. (2015) High Uric Acid Level Is a Risk Factor for Progression of IgA Nephropathy with Chronic Kidney Disease Stage G3a. Journal of Nephrology, 28, 451-456.

[33]   Akalin, E., Ganeshan, S.V., Winston, J. and Muntner, P. (2008) Hyperuricemia Is Associated with the Development of the Composite Outcomes of New Cardiovascular Events and Chronic Allograft Nephropathy. Transplantation, 86, 652-658.

[34]   Takayama, S., Kawamoto, R., Kusunoki, T., Abe, M. and Onji, M. (2012) Uric Acid Is an Independent Risk Factor for Carotid Atherosclerosis in a Japanese Elderly Population without Metabolic Syndrome. Cardiovascular Diabetology, 11, 2.

[35]   Taniguchi, Y., Hayashi, T., Tsumura, K., Endo, G., Fujii, S. and Okada, K. (2001) Serum Uric Acid and the Risk for Hypertension and Type 2 Diabetes in Japanese Men: The Osaka Health Survey. Journal of Hypertension, 19, 1209-1215.

[36]   Guo, M., Niu, J.Y., Li, S.R., Ye, X.W., Fang, H., Zhao, Y.P., et al. (2015) Gender Differences in the Association between Hyperuricemia and Diabetic Kidney Disease in Community Elderly Patients. Journal of Diabetes Complications, 29, 1042-1049.

[37]   Fessel, W.J. (1979) Renal Outcomes of Gout and Hyperuricemia. American Journal of Medicine, 67, 74-82.

[38]   Baldwin, W., McRae, S., Marek, G., Wymer, D., Pannu, V., Baylis, C., et al. (2011) Hyperuricemia as a Mediator of the Proinflammatory Endocrine Imbalance in the Adipose Tissue in a Murine Model of the Metabolic Syndrome. Diabetes, 60, 1258-1269.

[39]   Tsushima, Y., Nishizawa, H., Tochino, Y., Nakatsuji, H., Sekimoto, R., Nagao, H., et al. (2013) Uric Acid Secretion from Adipose Tissue and Its Increase in Obesity. Journal of Biological Chemistry, 288, 27138-27149.

[40]   Yamada, A., Sato, K.K., Kinuhata, S., Uehara, S., Endo, G., Hikita, Y., et al. (2016) Association of Visceral Fat and Liver Fat with Hyperuricemia. Arthritis Care and Research, 68, 553-561.

[41]   Matsuura, F., Yamashita, S., Nakamura, T., Nishida, M., Nozaki, S., Funahashi, T., et al. (1998) Effect of Visceral Fat Accumulation on Uric Acid Metabolism in Male Obese Subjects: Visceral Fat Obesity Is Linked More Closely to Overproduction of Uric Acid than Subcutaneous Fat Obesity. Metabolism, 47, 929-933.

[42]   Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K.R., Short, R.A., Glushakova, O., et al. (2006) A Causal Role for Uric Acid in Fructose-Induced Metabolic Syndrome. American Journal of Physiology Renal Physiology, 290, F625-F631.

[43]   Kataoka, H., Ariyama, Y., Deushi, M., Osaka, M., Nitta, K. and Yoshida, M. (2016) Inhibitory Effect of Serotonin Antagonist on Leukocyte-Endothelial Interactions in Vivo and in Vitro. PLoS ONE, 11, e0147929.

[44]   Sanchez-Lozada, L.G., Lanaspa, M.A., Cristobal-Garcia, M., Garcia-Arroyo, F., Soto, V., Cruz-Robles, D., et al. (2012) Uric Acid-Induced Endothelial Dysfunction Is Associated with Mitochondrial Alterations and Decreased Intracellular ATP Concentrations. Nephron Experimental Nephrology, 121, e71-e78.

[45]   Corry, D.B., Eslami, P., Yamamoto, K., Nyby, M.D., Makino, H. and Tuck, M.L. (2008) Uric Acid Stimulates Vascular Smooth Muscle Cell Proliferation and Oxidative Stress via the Vascular Renin-Angiotensin System. Journal of Hypertension, 26, 269-275.

[46]   Kanellis, J., Watanabe, S., Li, J.H., Kang, D.H., Li, P., Nakagawa, T., et al. (2003) Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells via Mitogen-Activated Protein Kinase and Cyclooxygenase-2. Hypertension, 41, 1287-1293.

[47]   Mazzali, M., Hughes, J., Kim, Y.G., Jefferson, J.A., Kang, D.H., Gordon, K.L., et al. (2001) Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism. Hypertension, 38, 1101-1106.

[48]   Nakagawa, T., Mazzali, M., Kang, D.H., Kanellis, J., Watanabe, S., Sanchez-Lozada, L.G., et al. (2003) Hyperuricemia Causes Glomerular Hypertrophy in the Rat. American Journal of Nephrology, 23, 2-7.

[49]   Kojima, C., Takei, T., Ogawa, T. and Nitta, K. (2012) Serum Complement C3 Predicts Renal Arteriolosclerosis in Non-Diabetic Chronic Kidney Disease. Journal of Atherosclerosis Thrombosis, 19, 854-861.

[50]   Kohagura, K., Kochi, M., Miyagi, T., Kinjyo, T., Maehara, Y., Nagahama, K., et al. (2013) An Association between Uric Acid Levels and Renal Arteriolopathy in Chronic Kidney Disease: A Biopsy-Based Study. Hypertension Research, 36, 43-49.